UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): August 16, 2016
CAREDX, INC.
(Exact name of registrant as specified in its charter)
Delaware | 001-36536 | 94-3316839 | ||
(State or other jurisdiction of incorporation) |
(Commission File No.) | (IRS Employer Identification Number) |
3260 Bayshore Boulevard
Brisbane, California 94005
(Address of principal executive offices, including zip code)
(415) 287-2300
(Registrants telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01 | Other Events. |
On August 16, 2016, CareDx, Inc. (the Company) filed a Notification of Late Filing on Form 12b-25 (the Form 12b-25) pertaining to its Quarterly Report on Form 10-Q for the quarter ended June 30, 2016 (the Form 10-Q), and issued a press release announcing that the Company filed the Form 12b-25 and intends to file the Form 10-Q by no later than August 22, 2016, the deadline afforded to it by filing the Form 12b-25. The reasons for the delay are more fully described in the copy of the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.
Item 9.01 | Financial Statements and Exhibits. |
(d) | Exhibits |
Exhibit |
Description | |
99.1 | Press release issued by CareDx, Inc. dated August 16, 2016 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CAREDX, INC. | ||||||||
Date: August 16, 2016 | By: | /s/ Charles Constanti | ||||||
Charles Constanti | ||||||||
Chief Financial Officer |
EXHIBIT INDEX
Exhibit |
Description | |
99.1 | Press release issued by CareDx, Inc. dated August 16, 2016 |
Exhibit 99.1
CareDx Reports Status of Form 10-Q
BRISBANE, CA, August 16, 2016: CareDx, Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that it filed with the Securities and Exchange Commission (SEC) a Form 12b-25 for an extension of the time for the filing of its Quarterly Report on Form 10-Q. The Company requested the extension because it needs additional time to complete the final review of its financial statements and other disclosures in the Form 10-Q, namely in light of the Companys recent acquisition of Allenex AB and the requirement to include Allenex ABs results in the Companys consolidated financial statements for the first time. Pursuant to SEC regulations, the Company has until Monday, August 22, 2016 to timely file its Form 10-Q, and the Company anticipates that it will file its Form 10-Q by that date. However, because the review is ongoing, no assurances can be given as to the definitive date on which the Form 10-Q will be filed.
About CareDx
CareDx, Inc., headquartered in Brisbane, California, is a global molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients. CareDx offers AlloMap®, a gene expression test that aids clinicians in identifying heart transplant patients with stable graft function who have a low probability of moderate to severe acute cellular rejection (ACR). CareDx is developing additional products for transplant monitoring using a variety of technologies, including AlloSure®, a proprietary next-generation sequencingbased test to detect donor-derived cell-free DNA (dd-cfDNA) after transplantation.
CareDx, with its presence through Olerup, also develops, manufactures, markets and sells high quality products that increase the chance of successful transplants by facilitating a better match between a donor and a recipient of stem cells and organs. Olerup SSP® is a set of HLA typing products used prior to hematopoietic stem cell/bone marrow transplantation and organ transplantation. XM-ONE® is the first standardized test that quickly identifies a patients antigens against HLA Class I, Class II or antibodies against a donors endothelium. For more information, please visit: www.CareDx.com.
Forward Looking Statements
In addition to historical information, this press release contains forward-looking statements with respect to our business including, but not limited to, statements regarding the anticipated timing of filing our Form 10-Q. These forward-looking statements are based upon information that is currently available to us and our current expectations, speak only as of the date hereof, and are subject to risks and uncertainties, including our ability to complete the work required to file the Form 10-Q in the time frame that is anticipated. We expressly disclaim any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.
Media Contacts CareDx | Media Contacts - Investor | |||
Molly Martell, Senior Director, Marketing |
Jamar Ismail, Vice President |
|||
T: +1 415-728-6307 |
Westwicke Partners, LLC |
|||
E: mmartell@caredx.com |
T: +1 415-513-1282 |
|||
E: jamar.ismail@westwicke.com |
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end